Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) specializes in developing oncology and dermatology therapies, and PV-10, its investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects, and, its oncology focus is on melanoma, breast cancer and cancers of the liver; also, the Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis, according to the company’s website (see here: www.ProvectusBio.com). SNNLive spoke with Peter R. Culpepper, Interim CEO and COO of Provectus Biopharmaceuticals, Inc. at the Growth Capital Expo 2016 in Las Vegas, NV.
In this video interview, Mr. Culpepper and our host discuss the following topics:
- Overview of Provectus Biopharmaceuticals, Inc.
- Clinical developments
- Changes in immunotherapy
- Goals and milestones for the company
For more information about Provectus Biopharmaceuticals, Inc., go to: www.ProvectusBio.com
The interview may contain forward looking statements about Provectus Biopharmaceuticals, Inc. See Provectus Biopharmaceuticals' periodic filings with the Securities and Exchange Commission for more complete information.
© 2017 Stock News Now
Supported by Superior Web Solutions